This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Pulmonary Arterial Hypertension
and you are
over 19
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months. Patients diagnosed with WHO Group I PAH who are on a stable regimen of commercial Ventavis® will be followed for a maximum of 2 years from the time of enrollment. Data will be collected via patient interview and review of the medical record. Quarterly data collection will include capture of medications and Ventavis® adherence data.

Provided treatments

  • Drug: Commercial Ventavis® (iloprost)
Tris trial is registered with FDA with number: NCT00902603. The sponsor of the trial is Actelion and it is looking for 148 volunteers for the current phase.
Official trial title:
Registry to Prospectively Evaluate Use of Ventavis® in Patients With Pulmonary Arterial Hypertension